ALSO NOTED: New constipation data; GSK touts Cervarix study; Spherix transitions to biotech; and much more...

> Wyeth and Progenics say that a three-month extended study of their constipation therapy produced positive data. Release

> GlaxoSmithKline says that the biggest study yet has produced impressive data on the effectiveness of Cervarix in preventing cervical cancer. It will need plenty of powerful data if it intends to grab market share from Gardasil. Release

> Spherix is transitioning to a full-fledged biotech company with the $17 million sale of its subsidiary to Active Network. Report

> StemCells has agreed to a stay on its patent lawsuit with Neuralstem. Report

And Finally... With billions of dollars of revenue on the line, Amgen is asking Congress not to make "precipitate changes" in the way that the government reimburses for anemia drugs. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.